Description
Developer of cardiac reperfusion therapies designed to prevent ischemia-reperfusion injury. The company's therapies involves the use of histone deacetylase (HDAC) inhibitors for reducing myocardial infarct size following acute myocardial infarction and restoring normal blood flow, thereby assisting physicians with an effective pharmaceutical intervention for protecting the cardiomyocyte from reperfusion injury.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 17-Sep-2020 | Completed | Out of Business | |||
1. Accelerator/Incubator | 01-Jan-2014 | Completed | Startup |